Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762115 | 0.80 | MAOB (0.49) | MAOBPOLBADORA2BHSD17B2CMA1 | |
| SCHEMBL5763478 | 0.80 | MAOB (0.49) | MAOBPTPN1KMT2AADORA2BHSD17B2 | |
| SCHEMBL11500782 | 0.79 | PSMB5 (0.48) | MAOBLMNAMAPK1KMT2AL3MBTL1 | |
| SCHEMBL12987640 | 0.77 | MAOB (0.56) | MAOBLMNAMAOAPSMB5PSMB8 | |
| SCHEMBL4139411 | 0.76 | MAOB (0.45) | MAOBKMT2AADORA2BHSD17B2PSMB5 | |
| SCHEMBL24898027 | 0.75 | MAOB (0.43) | MAOBLMNAPTPN1L3MBTL1ADORA2B | |
| SCHEMBL28394138 | 0.75 | MAOB (0.43) | MAOBPTPN1ADORA2BHSD17B2CMA1 | |
| SCHEMBL28392768 | 0.75 | MAOB (0.43) | MAOBPTPN1ADORA2BHSD17B2CMA1 | |
| SCHEMBL2960730 | 0.75 | MAOB (0.43) | MAOBPTPN1ADORA2BHSD17B2CMA1 | |
| SCHEMBL12911148 | 0.74 | CMA1 (0.44) | MAOBADORA2BHSD17B2CMA1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-4871864-A | Carbamoyloxythiophene fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-03 | — | — | US | disclosed |
| US-4839381-A | FUNGICIDES, PESTICIDES; RICE PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-13 | — | — | US | disclosed |
| US-4757085-A | Pharmaceuticals | BAYER AKTIENGESELLSCHAFT (DE) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | MAOB 2020/4885LMNA 1396/4885MAPK1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.